Biomedical Engineering Reference
In-Depth Information
Dikmen, Z. G., Gellert, G. C., Jackson, S., Gryaznov, S., Tressler, R., Dogan, P., Wright, W. E.
and Shay, J. W. 2005. In vivo inhibition of lung cancer by GRN163L: a novel human
telomerase inhibitor. Cancer Res 65:7866-73.
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J.
and Lydon, N. B. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth
of Bcr-Abl positive cells. Nat Med 2:561-6.
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B.,
Kantarjian, H., Capdeville, R., Ohno-Jones, S. and Sawyers, C. L. 2001. Efficacy and
safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
N Engl J Med 344:1031-7.
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N.,
Deininger, M. W., Silver, R. T., Goldman, J. M., Stone, R. M., Cervantes, F., Hochhaus,
A.,Powell,B.L.,Gabrilove,J.L.,Rousselot,P.,Reiffers,J.,Cornelissen,J.J.,Hughes,T.,
Agis, H., Fischer, T., Verhoef, G., Shepherd, J., Saglio, G., Gratwohl, A., Nielsen, J. L.,
Radich,J.P.,Simonsson,B.,Taylor,K.,Baccarani,M.,So,C.,Letvak,L.andLarson,R.A.
2006. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
N Engl J Med 355:2408-17.
Early Breast Cancer Trialists' Collaborative Group. 1998. Tamoxifen for early breast cancer:
an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet 351:1451-67.
Eaves, A. C., Barnett, M. J., Ponchio, L., Cashman, J. D., Petzer, A. L. and Eaves, C. J. 1998.
Differences between normal and CML stem cells: potential targets for clinical exploita-
tion. Stem Cells 16 Suppl 1:77-83; discussion 89.
Fialkow, P. J., Jacobson, R. J. and Papayannopoulou, T. 1977. Chronic myelocytic leukemia:
clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and mono-
cyte/macrophage. Am J Med 63:125-30.
Ford, C. E., Hamerton, J. L., Barnes, D. W. and Loutit, J. F. 1956. Cytological identification
of radiation-chimaeras. Nature 177:452-4.
Foster, A. E., Dotti, G., Lu, A., Andreeff, M., Goodell, M., Rooney, C. M. and
Brenner, M. K. 2006. Immune responses are induced against side-population
B-CLL ''stem cells'' by patient vaccination with hCD40/IL2 gene modified tumor
cells. Blood 108:721a-2a.
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H.,
Loh, M. L., Downing, J. R., Caligiuri, M. A., Bloomfield, C. D. and Lander, E. S. 1999.
Molecular classification of cancer: class discovery and class prediction by gene expression
monitoring. Science 286:531-7.
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N. and Sawyers, C. L.
2001. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or
amplification. Science 293:876-80.
Graham, S. M., Jorgensen, H. G., Allan, E., Pearson, C., Alcorn, M. J., Richmond, L. and
Holyoake, T. L. 2002. Primitive, quiescent, Philadelphia-positive stem cells from patients
with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99:319-25.
Graham, S. M., Vass, J. K., Holyoake, T. L. and Graham, G. J. 2007. Transcriptional analysis
of quiescent and proliferating CD34+ human haemopoietic cells from normal and CML
sources. Stem Cells 25:3111-20.
Groffen, J., Stephenson, J. R., Heisterkamp, N., de Klein, A., Bartram, C. R. and Grosveld, G.
1984. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on
chromosome 22. Cell 36:93-9.
Guenechea, G., Gan, O. I., Dorrell, C. and Dick, J. E. 2001. Distinct classes of human stem
cells that differ in proliferative and self-renewal potential. Nat Immunol 2:75-82.
Guzman, M. L., Neering, S. J., Upchurch, D., Grimes, B., Howard, D. S., Rizzieri, D. A.,
Luger, S. M. and Jordan, C. T. 2001. Nuclear factor-kappaB is constitutively activated in
primitive human acute myelogenous leukemia cells. Blood 98:2301-7.
